Browse > Article
http://dx.doi.org/10.4014/jmb.2205.05009

Bactericidal Effect of Cecropin A Fused Endolysin on Drug-Resistant Gram-Negative Pathogens  

Lim, Jeonghyun (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Hong, Juyeon (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Jung, Yongwon (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Ha, Jaewon (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Kim, Hwan (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Myung, Heejoon (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Song, Miryoung (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Publication Information
Journal of Microbiology and Biotechnology / v.32, no.6, 2022 , pp. 816-823 More about this Journal
Abstract
The rapid spread of superbugs leads to the escalation of infectious diseases, which threatens public health. Endolysins derived from bacteriophages are spotlighted as promising alternative antibiotics against multi-drug resistant bacteria. In this study, we isolated and characterized the novel Salmonella typhimurium phage PBST08. Bioinformatics analysis of the PBST08 genome revealed putative endolysin ST01 with a lysozyme-like domain. Since the lytic activity of the purified ST01 was minor, probably owing to the outer membrane, which blocks accessibility to peptidoglycan, antimicrobial peptide cecropin A (CecA) was fused to the N-terminus of ST01 to disrupt the outer membrane. The resulting CecA::ST01 has been shown to have increased bactericidal activity against gram-negative pathogens including Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, and Enterobacter cloacae and the most affected target was A. baumannii. In the presence of 0.25 µM CecA::ST01, A. baumannii ATCC 17978 strain was completely killed and CCARM 12026 strain was wiped out by 0.5 µM CecA::ST01, which is a clinical isolate of A. baumannii and resistant to multiple drugs including carbapenem. Moreover, the larvae of Galleria mellonella could be rescued up to 58% or 49% by the administration of CecA::ST01 upon infection by A. baumannii 17978 or CCARM 12026 strain. Finally, the antibacterial activity of CecA::ST01 was verified using 31 strains of five gram-negative pathogens by evaluation of minimal inhibitory concentration. Thus, the results indicate that a fusion of antimicrobial peptide to endolysin can enhance antibacterial activity and the spectrum of endolysin where multi-drug resistant gram-negative pathogens can be efficiently controlled.
Keywords
Endolysin; antimicrobial peptide; bacteriophage; gram-negative pathogens; multiple-drug resistance;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ligon BL. 2004. Penicillin: its discovery and early development. Semin. Pediatr. Infect. Dis 15: 52-57.   DOI
2 Lewis K. 2012. Antibiotics: recover the lost art of drug discovery. Nature 485: 439-440.   DOI
3 Jim O'Neill. 2016. Nat. Rev. Drug Discov. 15: 526.   DOI
4 Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268-281.   DOI
5 Bassetti M, Righi E, Vena A, Graziano E, Russo A, Peghin M. 2018. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr. Opin. Crit. Care 24: 385-393.   DOI
6 Traczewski MM, Ambler JE, Schuch R. 2021. Determination of MIC quality control parameters for exebacase, a novel lysin with antistaphylococcal activity. J. Clin. Microbiol. 59: e0311720.   DOI
7 Chegini Z, Khoshbayan A, Vesal S, Moradabadi A, Hashemi A, Shariati A. 2021. Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review. Ann. Clin. Microbiol. Antimicrob. 20: 30.   DOI
8 Bhargava K, Nath G, Bhargava A, Aseri GK, Jain N. 2021. Phage therapeutics: from promises to practices and prospectives. Appl. Microbiol. Biotechnol. 105: 9047-9067.   DOI
9 Mousavi SM, Babakhani S, Moradi L, Karami S, Shahbandeh M, Mirshekar M, et al. 2021. Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant Gram-negative bacteria. Curr. Microbiol. 78: 4023-4036.   DOI
10 Young I, Wang I, Roof WD. 2000. Phages will out: strategies of host cell lysis. Trends Microbiol. 8: 120-128.   DOI
11 Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P, et al. 2003. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52: 967-973.   DOI
12 Briers Y, Walmagh M, Grymonprez B, Biebl M, Pirnay J-P, Defraine V, et al. 2014. Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58: 3774-3784.   DOI
13 Abdelkader K, Gutierrez D, Tames-Caunedo H, Ruas-Madiedo P, Safaan A, Khairalla AS, et al. 2022. Engineering a lysin with intrinsic antibacterial activity (LysMK34) by cecropin A fusion enhances its antibacterial properties against Acinetobacter baumannii. Appl. Environ. Microbiol. 88: e0151521.   DOI
14 Kim MS, Kim YD, Hong SS, Park K, Ko KS, Myung H. 2015. Phage-encoded colanic acid-degrading enzyme permits lytic phage infection of a capsule-forming resistant mutant Escherichia coli strain. Appl. Environ. Microbiol. 81: 900-909.   DOI
15 Quevillon E, Silventoinen V, Pillai S, Harte N, Mulder N, Apweiler R, et al. 2005. InterProScan: protein domains identifier. Nucleic Acids Res. 33: W116-120.   DOI
16 Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8: 317-327.   DOI
17 Gerstmans H, Rodriguez-Rubio L, Lavigne R, Briers Y. 2016. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem. Soc. Trans 44: 123-128.   DOI
18 Meile S, Du J, Dunne M, Kilcher S, Loessner MJ. 2021. Engineering therapeutic phages for enhanced antibacterial efficacy. Curr. Opin. Virol. 52: 182-191.
19 Samson JE, Magadan AH, Sabri M, Moineau S. 2013. Revenge of the phages: defeating bacterial defences. Nat. Rev. Microbiol. 11: 675-687.   DOI
20 Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 98: 4107-4112.   DOI
21 Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, et al. 2012. Endolysins as antimicrobials. Adv. Virus Res. 83: 299-365.   DOI
22 Saeed SI, Mergani A, Aklilu E, Kamaruzzman NF. 2022. Antimicrobial peptides: bringing solution to the rising threats of antimicrobial resistance in livestock. Front. Vet. Sci. 9: 851052.   DOI
23 Moore AJ, Beazley WD, Bibby MC, Devine DA. 1996. Antimicrobial activity of cecropins. J. Antimicrob. Chemother. 37: 1077-1089.   DOI
24 Hockett KL, Baltrus DA. 2017. Use of the soft-agar overlay technique to screen for bacterially produced inhibitory compounds. J. Vis. Exp. 14: 55064.
25 Gouet P, Courcelle E, Stuart DI, Metoz F. 1999. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 15: 305-308.   DOI
26 Hong H-W, Kim YD, Jang J, Kim MS, Song M, Myung H. 2022. Combination effect of engineered endolysin EC340 with antibiotics. Front. Microbiol. 13: 821936.   DOI
27 Briers Y, Lavigne R. 2015. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol. 10: 377-390.   DOI
28 Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, et al. 2014. Engineered endolysin-based 'Artilysins' to combat multidrug-resistant gram-negative pathogens. mBio 5: e01379-01314.
29 Sievers F, Higgins DG. 2018. Clustal Omega for making accurate alignments of many protein sequences. Protein Sci. 27: 135-145.   DOI
30 Blasco L, Ambroa A, Trastoy R, Bleriot I, Moscoso M, Fernandez-Garcia L, et al. 2020. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Sci. Rep. 10: 7163.   DOI
31 Murray E, Draper LA, Ross RP, Hill C. 2021. The advantages and challenges of using endolysins in a clinical setting. Viruses 13: 680.   DOI
32 Martinez JL, Baquero F. 2014. Emergence and spread of antibiotic resistance: setting a parameter space. Ups. J. Med. Sci. 119: 68-77.   DOI